A nonrandomized, phase II study of sequential irinotecan and flavopiridol in patients with advanced hepatocellular carcinoma

Gastrointestinal Cancer Research

Volumn 5, Issue 6, 2013, Pages 185-189

  Ang, Celina ^a   O'Reilly, Eileen M ^a,b   Carvajal, Richard D ^a,b   Capanu, Marinela ^a   Gonen, Mithat ^a   Doyle, Laurence ^c   Ghossein, Ronald ^a   Schwartz, Lawrence ^d   Jacobs, Gria ^a   Ma, Jennifer ^a   Schwartz, Gary K ^a,b   Abou Alfa, Ghassan K ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL; IRINOTECAN; PROTEIN P53;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; KARNOFSKY PERFORMANCE STATUS; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL;

EID: 84873633072     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 144:646-674, 2011
2. Harper JW, Elledge SJ: Cdk inhibitors in development and cancer. Curr Opin Genet Dev 6:56-64, 1996
3. Chen YN, Sharma SK, Ramsey TM, et al: Selective killing of transformed cells by cyclin/cyclin dependent 2 kinase antagonists. Proc Natl Acad Sci USA 96:4325-4329, 1999
4. Hui AM, Makuuchi M, Li X: Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology 45:1635-1642, 1998
5. Matsuda Y, Ichida T: p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis. Med Mol Morphol 39:169-175, 2006
6. Kaur G, Stetler-Stevenson M, Sebers S, et al: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84:1736-1740, 1992
7. Shapiro GI: Preclinical and clinical development of the cyclin dependent kinase inhibitor flavopiridol. Clin Cancer Res 10:4270s-4275s, 2004
8. Wang LM, Ren DM: Flavopiridol, the first cyclin dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem 10:1058-1070, 2010
9. Reiner T, de las Pozas A, Perez-Stable C: Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the G_/T-15 transgenic mouse model of prostate cancer. Prostate 66:1487-1497, 2006
10. Jung CP, Motwani MV, Schwartz GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7:2527-2536, 2001
11. Motwani M, Hung C, Sirotnak FM, et al: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 7:4209-4219, 2001
12. Motwani M, Sirotnak FM, She Y, et al: Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 62:3950-3955, 2002
13. Ambrosini G, Seelman SL, Qin LX, et al: The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res 68:2312-2320, 2008
14. Shah MA, Kortmansky J, Motwani M, et al: A phase I trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 11:3836-3845, 2005
15. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
16. O'Reilly EM, Stuart KE, Sanz-Altamira PM, et al: A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 91:101-105, 2001
17. Huang CC, Wu MC, Xu GW, et al: Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84:262-264, 1992
18. Soong R, Robbins PD, Dix BR, et al: Concordance between p53 protein overexpression and gene mutation in a large series of human carcinomas. Hum Pathol 27:1050-1055, 1996
19. Tolbert DM, Noffsinger AE, Miller MA, et al: p53 immunoreactivity and single strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol 12:54-60, 1999
20. van de Ven S, Smit VT, Dekker TJ, et al: Discordances in ER, PR and HER2 receptors after neoadjuvant therapy in breast cancer. Cancer Treat Rev 37:422-430, 2011
21. Neubauer H, Gall C, Vogel U, et al: Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 28:1797-1804, 2008
22. Jung EU, Yoon JH, Lee YJ, et al: Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. Cancer Lett 298:9-15, 2010
23. Llovet JM, di Bisceglie AM, Bruix J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. Natl Cancer Inst 100:698-711, 2008
24. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-300, 2006
25. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
26. Rimassa L, Porta C, Borbath I, et al: Tivantinib (ARQ197) versus placebo in patients (pts) with hepatocellular carcinoma (HCC) who failed on systemic therapy: results of a randomized controlled phase II trial (RCT). J Clin Oncol 30S:2012 (abstr 4006)